Last updated: March 2026
How Much Does Ozempic Cost?
Ozempic, Wegovy, Mounjaro, and Zepbound (the GLP-1 receptor agonist class) are the most-searched prescription drugs of 2024-2025, but actual costs vary from $25/month to over $1,500/month depending on insurance, manufacturer copay assistance, dosage, and source. Our cost calculator estimates your real monthly out-of-pocket cost based on your insurance type (commercial, Medicare, Medicaid, no insurance), the specific GLP-1 drug, dosage strength, pharmacy choice, and whether you're considering manufacturer savings cards, compounded semaglutide / tirzepatide alternatives, or telehealth subscription services. Get a realistic price picture before starting therapy or switching options. ⚠️ Medical Disclaimer: This calculator provides general cost estimates for informational purposes only and is not medical advice. Drug prices, insurance coverage, and treatment decisions should always be discussed with a licensed healthcare professional and your insurance provider. Do not start, stop, or change any medication based on this tool. If you have questions about GLP-1 medications, dosing, side effects, or eligibility, consult your doctor or pharmacist.
Best Case
$0 – $50/mo
Commercial insurance + manufacturer savings card
Standard Coverage
$50 – $250/mo
Insurance with copay, no savings card
Direct-to-Patient
$399 – $799/mo
Lilly Direct vials, NovoCare direct
Cash / List Price
$800 – $1,500/mo
No insurance, no savings program
Ozempic & GLP-1 Value Calculator
Fill in the details below for an accurate estimate
Why Knowing Your Ozempic & GLP-1 Value Matters
GLP-1 medications have transformed Type 2 diabetes management and weight loss treatment, but cost remains the single biggest barrier to access. Brand-name list prices: Ozempic (semaglutide for diabetes) lists at $968-$1,029/month. Wegovy (semaglutide for weight loss) lists at $1,349/month. Mounjaro (tirzepatide for diabetes) lists at $1,069/month. Zepbound (tirzepatide for weight loss) lists at $1,059/month. With commercial insurance and manufacturer savings cards (Novo Nordisk for Ozempic/Wegovy, Eli Lilly for Mounjaro/Zepbound), eligible patients can pay as little as $25/month. Without insurance or with denied coverage, patients face the full list price. Compounded semaglutide and tirzepatide from telehealth services (Hims, Ro, Eden, Henry Meds, Mochi Health) have emerged at $150-$400/month and serve patients without insurance access. Knowing your real monthly cost matters for budgeting (these are typically multi-year therapies), comparing brand vs. compounded options, and choosing the right pharmacy or telehealth provider.
Key Factors That Affect Ozempic & GLP-1 Value
Understanding what drives the price of ozempic & glp-1 helps you get the most accurate valuation.
Insurance Coverage Type
Commercial insurance with GLP-1 coverage: $0-$50/month with manufacturer savings card (Wegovy/Zepbound savings cards offer $0/month for eligible commercially insured patients). Commercial insurance without GLP-1 coverage (most common for weight-loss indication): full list price after rejection, often appealable. Medicare: limited coverage. Ozempic/Mounjaro covered for Type 2 diabetes only (not weight loss). Wegovy covered as of 2024 for cardiovascular risk reduction in Medicare patients with established cardiovascular disease, but with significant coinsurance. Medicaid: state-by-state coverage varies dramatically. Most state Medicaids cover Ozempic/Mounjaro for diabetes but limit Wegovy/Zepbound to BMI 40+ or comorbid conditions. No insurance: brand-name pricing $968-$1,500/month full price.
Specific Medication & Dosage
Drug pricing (cash list price for monthly supply): Ozempic (semaglutide injection, diabetes): $968-$1,029/month for 0.25mg, 0.5mg, 1mg, 2mg pens. Wegovy (semaglutide injection, weight loss): $1,349/month for 0.25mg through 2.4mg dose pens. Mounjaro (tirzepatide injection, diabetes): $1,069/month for 2.5mg-15mg pens. Zepbound (tirzepatide injection, weight loss): $1,059/month for vials, $799/month for vials through Lilly Direct (May 2024 launch, lower-cost direct-to-patient option). Higher doses cost the same as lower doses since each pen contains a fixed monthly supply.
Manufacturer Savings Cards & Patient Assistance
Novo Nordisk Wegovy SaveCard: as low as $0/month for eligible commercial insurance patients with coverage, $650/month savings for those without coverage, capped at 13 fills. Lilly Zepbound Savings Card: $25/month with commercial insurance coverage, $463/month savings for those without coverage. Patient Assistance Programs (PAPs): both Novo Nordisk and Eli Lilly offer free medication for patients earning under specific income thresholds (typically under 400% of federal poverty level) with no insurance. These programs are underutilized but available. Application requires income documentation and physician participation.
Compounded Semaglutide & Tirzepatide (Telehealth)
Compounded GLP-1 medications became widely available during the FDA shortage list (Ozempic listed October 2022 - October 2024, Wegovy until February 2025, Tirzepatide products until October 2024). Telehealth providers (Hims/Hers, Ro, Eden, Henry Meds, Mochi Health, Sequence) offered compounded versions at $150-$400/month. As of 2025, with shortages resolved, compounded versions are increasingly restricted under FDA enforcement. Patients should verify their telehealth provider uses an accredited 503A pharmacy and that compounding is still legal under current FDA guidance for their specific medication. Many telehealth GLP-1 services have transitioned to brand-name authorized distribution at the new lower-priced direct-to-patient prices.
Pharmacy Choice & Discount Programs
Pharmacy choice affects cash prices significantly. Costco Pharmacy and Sam's Club Pharmacy typically have the lowest cash prices on GLP-1s ($800-$950 for Ozempic vs. $968-$1,029 list). GoodRx coupons: GLP-1 medications generally don't have meaningful GoodRx discounts due to manufacturer rebate structures (savings rarely exceed 10%). SingleCare and similar programs offer 5-15% discounts at certain pharmacies. Mark Cuban Cost Plus Drug Company does NOT carry GLP-1 medications (these are still under brand-name patent protection). Lilly Direct (launched May 2024) offers Zepbound vials at $399-$799/month directly to patients without insurance and with telehealth prescription validation.
Tips for Valuing Ozempic & GLP-1
Get the most accurate estimate by following these tips when evaluating your ozempic & glp-1.
Apply for the manufacturer savings card BEFORE filling your prescription. Wegovy SaveCard and Zepbound Savings Card both offer instant activation online, no income verification required for commercially insured patients.
If your insurance denies GLP-1 coverage for weight loss, ask your prescribing physician to file a prior authorization with documentation of comorbidities (hypertension, sleep apnea, prediabetes). Approval rates after appeal are 40-60%.
Check Costco/Sam's Club Pharmacy cash prices even if you have insurance. Sometimes their cash price plus your insurance reimbursement netting is better than your insurance copay.
If considering compounded GLP-1 from telehealth, verify the pharmacy is 503A-accredited, the compound is legal under current FDA guidance, and the provider does ongoing physician monitoring (not just initial prescription).
Ozempic & GLP-1 Market Insights
The GLP-1 market has reshaped pharmaceutical pricing and patient access conversations. As of 2025, Novo Nordisk and Eli Lilly together generate over $50 billion annually from GLP-1 medications, making them among the best-selling drug classes in history. Insurance coverage has lagged demand significantly. Most commercial plans cover GLP-1s for Type 2 diabetes (Ozempic, Mounjaro) but exclude weight-loss indications (Wegovy, Zepbound) unless the patient meets BMI criteria with comorbid conditions. Medicare's Wegovy coverage expansion (March 2024) for established cardiovascular disease was a landmark policy change. State Medicaid coverage continues to expand for weight-loss indications as long-term outcome studies show CV and metabolic benefits. The compounded semaglutide / tirzepatide market is in transition. The FDA removed both drug shortages from active status in 2024-2025, and compounding is increasingly restricted to specific patient situations (allergies to FDA-approved formulation, dose customizations, etc.). Many telehealth services have transitioned to brand-name distribution. Lilly Direct's launch of Zepbound vials at $399/month single-dose was a major pricing disruption. Novo Nordisk responded with NovoCare's $499/month Wegovy direct-to-patient program in 2025.
Find Out What Your Ozempic & GLP-1 Are Worth
Upload a photo now and get a free AI-powered valuation in seconds. No sign-up required.
Also available on
Ozempic & GLP-1 Valuation FAQ
How much does Ozempic cost without insurance?
Without insurance, Ozempic lists at $968-$1,029/month for any dosage strength (0.25mg through 2mg pens, each pen contains a 1-month supply). Costco Pharmacy and Sam's Club Pharmacy typically offer cash prices of $800-$950/month. Novo Nordisk's NovoCare patient assistance program may provide free Ozempic for patients earning under approximately $60,000/year (single) or $80,000/year (family) with no insurance. The Ozempic Savings Card is for commercially insured patients only and does not help cash payers. Compounded semaglutide from telehealth (where legally available) ranges $150-$400/month but availability has narrowed since FDA shortage status changes.
Does Medicare cover Ozempic, Wegovy, or Mounjaro?
Medicare Part D covers Ozempic and Mounjaro for Type 2 diabetes (the FDA-approved indication). Coverage is at standard tier pricing with copays of $30-$150/month depending on plan and tier. Wegovy was added to Medicare Part D coverage in March 2024 specifically for patients with established cardiovascular disease as cardiovascular risk reduction. Standalone weight-loss coverage for Wegovy or Zepbound under Medicare remains excluded by federal law (Medicare cannot cover drugs solely for weight loss). Zepbound coverage for Medicare is currently for sleep apnea (FDA-approved indication December 2024) under specific Part D plans.
What's the difference between Ozempic, Wegovy, Mounjaro, and Zepbound?
Ozempic and Wegovy contain the same active ingredient (semaglutide) but at different dose ranges and FDA approvals. Ozempic (Type 2 diabetes, doses up to 2mg) and Wegovy (chronic weight management, doses up to 2.4mg). Mounjaro and Zepbound contain tirzepatide (a dual GLP-1 + GIP agonist), with Mounjaro approved for Type 2 diabetes and Zepbound for chronic weight management and obstructive sleep apnea. Tirzepatide-based drugs (Mounjaro/Zepbound) have shown stronger weight-loss results in head-to-head trials than semaglutide (Ozempic/Wegovy). Cost is similar across all four: $1,000-$1,500/month list price.
Are compounded semaglutide and tirzepatide cheaper alternatives still available?
It depends on your jurisdiction and the current FDA shortage status. The FDA removed semaglutide products from the shortage list in February 2025 and tirzepatide products in October 2024. Once a drug is off the shortage list, large-scale compounding by 503B outsourcing facilities is no longer permitted. 503A compounding pharmacies can still compound for specific patient needs (allergy to brand inactive ingredients, dose customization) on individual prescription, but mass marketing of $200/month compounds via telehealth is increasingly restricted. Many former compounding telehealth providers (Hims, Ro, Henry Meds) have transitioned to selling brand-name medications through partnerships with Lilly Direct and NovoCare at the new lower direct-to-patient prices. Verify your provider's pharmacy is FDA-compliant and that the compound is legal for your specific situation.